DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Valstar (Valrubicin) - Summary

 
 



VALSTAR SUMMARY

Valrubicin (N-trifluoroacetyladriamycin-14-valerate), a semisynthetic analog of the anthra-cycline doxorubicin, is a cytotoxic agent.

VALSTAR is indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.


See all Valstar indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Valstar (Valrubicin)

Gallbladder Cancer
Source: MedicineNet Aches, Pain, Fever Specialty [2014.04.18]
Title: Gallbladder Cancer
Category: Diseases and Conditions
Created: 4/2/2008 12:00:00 AM
Last Editorial Review: 4/18/2014 12:00:00 AM

OncoBriefs: Chemo for Bladder Cancer, Myeloma Care (CME/CE)
Source: MedPage Today Oncology/Hematology [2014.04.17]
(MedPage Today) -- The vast majority of patients with muscle-invasive bladder cancer do not receive chemotherapy, despite evidence of a significant survival benefit, investigators concluded after a 2,000-case review.

Chemotherapy 'Vastly Underutilized' in Bladder Cancer
Source: Medscape Hematology-Oncology Headlines [2014.04.16]
Neoadjuvant use hovers at 4%, whereas adjuvant chemotherapy is increasing in popularity, according to data from the Ontario Cancer Registry.
Medscape Medical News

In Bladder Cancer, ERCC1 Status Predicts Chemo Response
Source: Medscape Hematology-Oncology Headlines [2014.04.15]
Survival is better if patients treated with neoadjuvant chemotherapy before radical cystectomy test positive for ECCR1, a protein involved in DNA repair, new research suggests.
Medscape Medical News

Chemotherapy before or after surgery for high-risk bladder cancer improves survival, but is not routinely administered
Source: Cancer / Oncology News From Medical News Today [2014.04.14]
Contrary to treatment guidelines for high-risk bladder cancer, chemotherapy before or after surgery is not commonly used in routine clinical practice.

more news >>

Published Studies Related to Valstar (Valrubicin)

Factors affecting valrubicin response in patients with bacillus Calmette-Guerin-refractory bladder carcinoma in situ. [2011.05]
OBJECTIVE: Patients with bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the bladder are candidates for intravesical (IVe) valrubicin. This post-hoc analysis of data from the pivotal phase 3, prospective, open-label study of valrubicin evaluated the effects of patient characteristics and past treatments on the response to valrubicin... CONCLUSIONS: In these patients with BCG-refractory CIS, complete responders to valrubicin did not differ significantly from partial or nonresponders in the number of prior courses or instillations. The results suggest that therapy with valrubicin may be considered in appropriate candidates who have not responded to prior therapies. Cystectomy should be reconsidered when valrubicin treatment fails.

Topical application of valrubicin has a beneficial effect on developing skin tumors. [2010.08]
Valrubicin is a second generation anthracycline characterized by an excellent safety profile presenting no skin toxicity or necrosis upon contact...

Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation model. [2010.02]
Valrubicin is a cytostatic drug currently approved by the American Federal Drug Administration as a trademarked Valstar sterile solution for the treatment of bladder cancer. Valrubicin has shown an excellent therapeutic potential with minimal toxicity.

more studies >>

Clinical Trials Related to Valstar (Valrubicin)

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma [Recruiting]
The purpose of this study is to learn more about how well the drug valrubicin (VALSTARŪ) works to help treat the patient's cancer when administered through a nephrostomy tube inserted through their back into their kidney. The study is also being done to determine how safe and easy it is to tolerate valrubicin at specific dose levels, as well as the way in which the drug is eliminated from the human body (Pharmacokinetics or PK).

Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer [Not yet recruiting]
The use of a designed viral vector that can destroy cancer cells while leaving normal cells largely unharmed. The virus also stimulates an immunological response by producing a special factor (GM-CSF) to attract and promote the development of dendritic and T effector cells. It forms the hypothesis that this regimen may be used for people who have failed current forms of treatment and are recommended for cystectomy. It is with hope that this novel therapy will be able to delay or potentially avoid cystectomy for this patient population. Bladder instillation of this agent causes little long lasting side effects and may drastically improve the stimulation of the immune system for local cancer cell death as well as destroying those tumor cells that may have travelled to regional lymph nodes or distant organs.

more trials >>


Page last updated: 2014-04-18

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012